• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

Levosimendan on Heart Failure

August 26, 2024

Levosimendan is a calcium sensitizer that produces a potent effect on the heart muscle. Acting as a positive inotrope, it strengthens the heart’s contractions, making it pump more efficiently. In comparison with other inotropes, levosimendan does not cause unwanted arrythmogenic effects.

In an aging population, chronic diseases are expected to have increasing prevalence. One such disease is heart failure with preserved ejection fraction (HFpEF).

Recently, an animal study was completed to investigate the possibility that HFpEF may be controlled using this inodilator. ZSF1 obese rats were used as a preclinical surrogate model for HFpEF. The animals were treated for 6 weeks with 1 mg/kg/day levosimendan in drinking water. Another group was submitted to i.v. levosimendan infusion to determine the acute effects.

Both types of treatment seemed to show beneficial haemodynamic effects in this study. However, as with many animal models of human diseases, this model has some limitations. Further research should carefully appraise the effectiveness of this treatment on an aging population of HFpEF.

Moreira-Costa L, Tavares-Silva M, Almeida-Coelho J, et al. Acute and chronic effects of levosimendan in the ZSF1 obese rat model of heart failure with preserved ejection fraction. Eur J Pharmacol. 2024 Mar 5:966:176336. PMID: 38272343

Categories: News

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only